Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis

BMC Gastroenterology

Stephanie Reid¹  Julia Trahey²  John Fardy²  Xin Mu² 

[1] Discipline of Laboratory Medicine, Health Sciences Centre, Memorial University of Newfoundland, St. John’s, Canada;Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada;Discipline of Medicine, Memorial University of Newfoundland, 300 Prince Philip Drive, A1B 3V6, St. John’s, NL, Canada;Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada;

关键词: Ixekizumab;    Inflammatory bowel disease;    Drug-associated colitis;    Psoriasis;    Case report;   

DOI  :  10.1186/s12876-021-01936-w

来源: Springer

【 摘 要 】

BackgroundIxekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to induce and exacerbate inflammatory bowel disease (IBD).Case presentationHere we report the new onset of severe drug-associated colitis with surgical complications in a 45-year-old male patient who was receiving Ixekizumab therapy for chronic plaque psoriasis. Review of the patient’s colonic pathology demonstrated acute inflammatory changes with features of Crohn’s disease. The patient remained disease-free 9-months following his hospitalization and cessation of Ixekizumab.ConclusionsThis case raises suspicion for an association between Ixekizumab and IBD and calls on clinicians to have heightened awareness of potential risks before prescribing anti-IL-17 agents.

【 授权许可】

CC BY